Cryo Stasis Inc. specializes in innovative cell and gene therapy solutions, particularly through its proprietary Woolii™ SU Platform, which enables the preservation of biological materials without freezing. This technology, rooted in the research of biochemist Olga Kukal, utilizes a unique combination of media, temperature, and pressure to maintain optimal cell viability and function. With a focus on clinically proven methods, Cryo Stasis aims to integrate seamlessly into manufacturing processes, enhancing the production capabilities of FDA-approved therapies. The company is positioned to capitalize on the projected 21% annual growth in therapeutics, making it a compelling investment opportunity in the biopreservation market.
Something looks off?